[go: up one dir, main page]

BR0212151A - Use of compounds to treat conditions resulting from corneal nerve damage following lasik and other eye surgery or trauma - Google Patents

Use of compounds to treat conditions resulting from corneal nerve damage following lasik and other eye surgery or trauma

Info

Publication number
BR0212151A
BR0212151A BR0212151-4A BR0212151A BR0212151A BR 0212151 A BR0212151 A BR 0212151A BR 0212151 A BR0212151 A BR 0212151A BR 0212151 A BR0212151 A BR 0212151A
Authority
BR
Brazil
Prior art keywords
trauma
nerve damage
compounds
conditions resulting
treat conditions
Prior art date
Application number
BR0212151-4A
Other languages
Portuguese (pt)
Inventor
Mark R Hellberg
Iok-Hou Pang
John M Yanni
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0212151A publication Critical patent/BR0212151A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"USO DE COMPOSTOS PARA TRATAR CONDIçõES RESULTANTES DE DANO AO NERVO CORNEANO APóS CIRURGIAS DE LASIK E OUTRAS OCULARES OU TRAUMAS". A presente invenção refere-se métodos para o tratamento de condições resultantes de dano ao nervo corneano após cirurgias de LASIK e outras oculares ou trauma."USE OF COMPOUNDS TO TREAT CONDITIONS RESULTING FROM CORNEAN NERVE DAMAGE AFTER LASIK SURGERIES AND OTHER EYE OR TRAUMA". The present invention relates to methods for treating conditions resulting from corneal nerve damage following LASIK and other eye surgeries or trauma.

BR0212151-4A 2001-08-29 2002-07-23 Use of compounds to treat conditions resulting from corneal nerve damage following lasik and other eye surgery or trauma BR0212151A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31565201P 2001-08-29 2001-08-29
PCT/US2002/023871 WO2003020281A1 (en) 2001-08-29 2002-07-23 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma

Publications (1)

Publication Number Publication Date
BR0212151A true BR0212151A (en) 2004-08-24

Family

ID=23225436

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212151-4A BR0212151A (en) 2001-08-29 2002-07-23 Use of compounds to treat conditions resulting from corneal nerve damage following lasik and other eye surgery or trauma

Country Status (10)

Country Link
EP (1) EP1420791A4 (en)
JP (1) JP2005502678A (en)
CN (1) CN1549718A (en)
AR (1) AR036194A1 (en)
BR (1) BR0212151A (en)
CA (1) CA2455896A1 (en)
MX (1) MXPA04001255A (en)
PL (1) PL368565A1 (en)
WO (1) WO2003020281A1 (en)
ZA (1) ZA200400837B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091662A1 (en) * 2003-04-18 2004-10-28 Senju Pharmaceutical Co. Ltd. Agent for repairing corneal perception
ES2234428B1 (en) * 2003-12-09 2006-11-01 Universidad Miguel Hernandez COMPOUNDS FOR THE TREATMENT OF THE DROUGHT OF THE OCULAR SURFACE CAUSED BY THE PHOTO-REFRECTIVE SURGERY.
CA2563882A1 (en) * 2004-04-23 2005-11-03 Senju Pharmaceutical Co., Ltd. Corneal neuritogenesis promoter containing pacap and its derivative
US7485654B2 (en) * 2004-06-03 2009-02-03 Senju Pharmaceutical Co., Ltd. Corneal perception recovery drug containing amide compound
JPWO2006098292A1 (en) 2005-03-15 2008-08-21 小野薬品工業株式会社 Eye disease treatment
CN113350326B (en) * 2021-07-28 2023-03-17 爱尔眼科医院集团股份有限公司 Application of compound LM22B-10 in preparation of corneal epithelium and nerve injury treatment drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
FR2672213B1 (en) * 1991-02-05 1995-03-10 Sanofi Sa USE OF 4- (3-TRIFLUOROMETHYLPHENYL) -1,2,3,6-TETRAHYDROPYRIDINIC DERIVATIVES AS SENSORS OF FREE RADICALS.
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
US5604244A (en) * 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
TWI246421B (en) * 1998-12-03 2006-01-01 Alcon Mfg Ltd Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
WO2001085152A2 (en) * 2000-05-10 2001-11-15 Alcon, Inc. R-eliprodil for treating glaucoma

Also Published As

Publication number Publication date
ZA200400837B (en) 2005-02-02
EP1420791A1 (en) 2004-05-26
JP2005502678A (en) 2005-01-27
CA2455896A1 (en) 2003-03-13
PL368565A1 (en) 2005-04-04
WO2003020281A1 (en) 2003-03-13
MXPA04001255A (en) 2004-05-27
CN1549718A (en) 2004-11-24
EP1420791A4 (en) 2004-09-15
AR036194A1 (en) 2004-08-18

Similar Documents

Publication Publication Date Title
BR0210241A (en) Pyanoindazoles and their use in the treatment of glaucoma
DE69521620D1 (en) USE OF 9-DEOXYPROSTAGLAND IN DERIVATIVES FOR TREATING GLAUCOMA
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
DE59409312D1 (en) IMIDAZOPYRIDINE AND THEIR APPLICATION FOR THE TREATMENT OF STOMELINE DISEASES
ATE303757T1 (en) TREATMENT OF EYE DISEASES
ATE238792T1 (en) USE OF MACROLIDS TO TREAT GLAUCOMA
DE69930271D1 (en) MEDICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
WO2000018387A3 (en) Antibiotic compositions for treatment of the eye, ear and nose
WO2001068053A3 (en) Methods and compositions for treating and preventing posterior segment ophthalmic disorders
BR9907715A (en) Ophthalmic composition / method for treating corneal injury and / or impaired corneal esthesia, dry eye syndrome, hypolarcrimation and use of an aldose reductase inhibitor
BR0212151A (en) Use of compounds to treat conditions resulting from corneal nerve damage following lasik and other eye surgery or trauma
MXPA02011921A (en) INHIBITORS OF DIPEPTIDASE ACID N-ACETILATED-ALPHA-LINKED FOR THE TREATMENT OF RETINIAN DISORDERS AND GLAUCONA.
DE602005008935D1 (en) STATINE FOR THE TREATMENT OF OCCULAR HYPERTONIA AND GLAUCOMA
DE60138385D1 (en) REMEDIES FOR THE TREATMENT OF DISEASES OF THE SEHNERV
ATE409491T1 (en) ORHTHALMOLOGICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSION
BR0017340A (en) Treatment of trauma and other indications
BR0316775A (en) New benzopyran analogues and their use for treating glaucoma
MXPA05014143A (en) Coumarin derivatives for the treatment of ophthalmic disorders.
ATE215824T1 (en) AGENTS FOR REDUCING INTERNAL EYE PRESSURE
AU4397197A (en) Subepithelial turbidity inhibitor
BRPI0417549A (en) superoxide dismutase mimetics for the treatment of optic and retinal nerve injury
BR0212274A (en) Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma.
BR0215752A (en) Pyanoindazoles and their use in the treatment of glaucoma
RU95107870A (en) Method to treat postoperative ciliochorioidal detachment
BR0015486A (en) Neurophylline ligands for treating eye conditions

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired